Group 2 Innate Lymphoid Cells in Patients With Severe Atopic Dermatitis on Dupilumab

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.059
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Gamaglobulin Infusion in Patients With Severe Atopic Dermatitis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Induction of Human Regulatory Innate Lymphoid Cells From Group 2 Innate Lymphoid Cells by Retinoic Acid

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Reduced Numbers of Circulating Group 2 Innate Lymphoid Cells in Patients With Common Variable Immunodeficiency

European Journal of Immunology
AllergyImmunology
2017English

Real‐world Use of Dupilumab for 53 Patients With Atopic Dermatitis in Japan

Journal of Cutaneous Immunology and Allergy
2020English

Pulmonary Group 2 Innate Lymphoid Cells: Surprises and Challenges

Mucosal Immunology
AllergyImmunology
2019English

PD-1 Regulates KLRG1 + Group 2 Innate Lymphoid Cells

Journal of Experimental Medicine
MedicineAllergyImmunology
2017English

Effectiveness of Dupilumab Treatment in 95 Patients With Atopic Dermatitis: Daily Practice Data

British Journal of Dermatology
DermatologyMedicine
2019English

Dupilumab for the Treatment of Atopic Dermatitis

Prescriber
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy